ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SDGR vs PVLA // 10Y YIELD & FRED MACRO BETA

Schrodinger Inc. (NASDAQ) VS. Palvella Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SDGR 2 — PVLA 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SDGR VS. PVLA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SDGR PVLA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 55.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -27.90% -7.10 PVLA /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield 0.56% -1.14% +1.70 SDGR /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -40.40% — — TIE /net-margins <GO>
Revenue Growth (YoY) 23.30% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.64 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 2/9 +5.00 SDGR /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.8 57.6 -5.80 PVLA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.03B $2.11B -$75.6M PVLA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SDGR REV PVLA REV SDGR GROSS % PVLA GROSS % SDGR FCF PVLA FCF
FY 2025 $255.9M $108.1M 55.7% — $12.5M -$25.0M
FY 2024 $207.5M $39.5M 63.6% — -$164.7M -$10.8M
FY 2023 $216.7M $42.8M — — -$136.7M -$13.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SDGR // BETA —
PVLA // BETA —